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PerspectivesBiologicalmodelsofmental illness: implications for
therapy development
Systems approaches are needed to recognise the complexity of the biological bases
of psychiatric diseasehe bases of mental disorders can best be
understood as a complex interplay betweenPhilip M Boyce
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doi: 10.5694/mja16.00260T biological, psychological, social and lifestyle
factors: a classic bio-psycho-social-lifestyle model. There
are undoubtedly some disorders where a biologicalmodel
alone ismore appropriate— this applies particularly to the
psychotic disorders— but even in such cases it must be
acknowledged that these illnesses are strongly inﬂuenced
by psychosocial and lifestyle factors. What makes a
biological understanding of mental illnesses necessary,
however, is that it opens the way for the development of
rational treatments. This has been thequest since antiquity,
with treatments predicated on the putative underlying
biological causes: purging and bleeding patients to correct
imbalances in the humours to treat melancholia, which
was attributed to an excess of black bile, or removing
sources of focal infection, such as the teeth, tonsils and
even the colon, that were once regarded as causingmental
disorders. While these models perhaps now seem
far-fetched, they were not entirely implausible when
one considers contemporary neuro-endocrine and
neuro-inﬂammatory models of mental illness.
Biological explanations of mental disorders gained
momentum in the early 1950s through a series of fortuitous
discoveries in psychopharmacology coupled with “reverse
engineering”. Firstly, chlorpromazine, initially synthesised
as an antihistamine, unexpectedly alleviated hallucinations
and other symptoms of schizophrenia. Similarly, it was
noticed that iproniazid, originally used to treat tuberculosis,
made some lucky patients inappropriately happy;
imipramine (considered to be another antihistamine) and
structurally similar to chlorpromazine, was also found to
have antidepressant activity.
As chemical neuroanatomy advanced from the late 1950s,
models ofmental illnesswere developed. For example, the
dopamine hypothesis of schizophrenia was based, in part,
on the discovery that chlorpromazine inhibited
dopaminergic transmission, leading to further drugs being
developed that blocked dopamine D2 receptors. It was
subsequently found that imipramine and monoamine
oxidase inhibitors with antidepressant properties also
modiﬁed catecholaminergic transmission, and depression
was consequently seen as the result of reduced
catecholamine levels in the brain. This conceptwas reﬁned
by incorporating serotonin (5-HT) and the complex
regulation of multiple monoamine receptor types into the
model, and the development of agents that speciﬁcally
targeted serotonin transmission, the selective serotonin re-
uptake inhibitors (SSRIs). This focus on the monoamines
and other neurotransmitters led to new me-toomedications, the key elements ofwhich remained blocking
D2 receptors in schizophrenia and stimulating serotonin
and noradrenaline receptors in depressive and anxiety
disorders. The robust antipsychotic properties of
clozapine, despite its being only a weak D2 receptor
antagonist, spurred exploration of other neurotransmitters
implicated in schizophrenia, including roles for 5-HT2A
and 5-HT2C receptors, leading to the development of
further second generation antipsychotics.
The winding road to new therapies
While these neurotransmitter hypotheses are of great
heuristic value, they do not sufﬁciently explain mental
disorders, nor does targeting these transmitter systems
completely ameliorate their symptoms. Further, more
recent ﬁndings have implicated several other pathways.
So howdowedevelop the next generation of therapies for
people with psychiatric disorders? The traditional route
was to identify a singular molecular focus, which could
then be targeted. While this approach has intrinsic
scientiﬁc rigour, is tightly hypothesis-driven, and has
mechanistic appeal, it has not been a fruitful approach for
developing truly novel therapies. It is also problematic for
mental disorders, for which there is no clearly identiﬁed
ﬁnal common functional pathway, and where the
patterns of biomarker abnormalities in seemingly
different conditions overlap to a signiﬁcant degree. This
problem is partially the product of existing
phenomenologically based diagnostic systems, such as
the Diagnostic and statistical manual of mental disorders
(DSM), which cannot accurately deﬁne phenotypes that
are based on phenomenology rather than biological sub-
categories. To overcome the problem, the NationalMJA 204 (9) j 16 May 2016 339
“these are not
siloed
systems . they
interact
intimately in
complex and
sometimes
unpredictable
ways”
PerspectivesInstitute of Mental Health (United States) has adopted a
shift in emphasis in its Research Domain Criteria (RDoC)
from diagnosis to symptom domains.1 These symptom
domains— negative valence, positive valence, cognitive
function, arousal, and social process systems— are
mapped against the underlying genes, molecules, neural
circuits and neurophysiology that putatively underpin
them. While this new approach is a welcome injection of
novel thinking, it matches clinical needs poorly, and we
are yet to see positive outcomes from its application.
There are nevertheless hopes that it will help elucidate
brain processes and models of mental illness that can be
used to identify therapeutic targets.
One can also adopt systems-based philosophies that are
more broadly directed at networks involved in the
pathophysiology of mental illness.2 This approach is
gaining traction with the identiﬁcation of a number of
non-monoaminergic systems and processes that have
been implicated in the pathogenesis of several psychiatric
disorders, including inﬂammation, dysregulated
oxidative signalling, neurogenesis, apoptosis and
mitochondrial dysfunction. These functionally
interacting cellular pathways combine in contributing to
the dysregulation of systems and networks in the genesis
of many non-communicable disorders, which are rarely
the outcome of an abnormality in a single element. The
gut microbiome has recently been identiﬁed as a critical
system in its own right, with profound impacts on
immune regulation and other systems. As it can be
inﬂuenced by diet, it is correspondingly being seen as a
plastic target in the development of novel therapies.3
Anumberof studies have examined such systems, and this
approach remains one of the more promising avenues for
therapeutic development. It must be noted that many of
the knowndrivers of psychopathology, as varied as stress,
poor diet, smoking, physical inactivity, sleep disturbance
and vitamin D insufﬁciency, have common effects upon
inﬂammation and oxidative stress, for example. While
suchdrivers of psychopathologyare deemed tobe lifestyle
factors, they exert their effects through their impact on
recognised biological systems. By the same token,
seemingly psychological risk factors, such as early trauma,
can lead tobiological changes throughepigenetic effects on
the reactivity of the hypothalamicepituitaryeadrenal axis
and the activity of the immune system.
Putting it all together
An integrative model incorporating lifestyle and risk
variants, operative neurobiological pathways, and the
impact of those pathways on brain structure and function
is thus beginning to emerge. The systems biology
approach emphasises the fact that these are not siloed
systems and that they interact intimately in complex and
sometimes unpredictableways. To capture the underlying
pathophysiology of such multisystem dysfunction, novel
molecular techniques, including the “omics” platforms,
are needed, buttressed by big data analytic techniques.
Researchers have leveraged these systems approaches to
productively target inﬂammation, and a number of leads340 MJA 204 (9) j 16 May 2016arebeing followedup, including the therapeutic beneﬁts of
agents such as celecoxib, aspirin, statins, minocycline, and
antibodies to immune factors (such as tumor necrosis
factor [TNF-a]).4 Given the ubiquity of oxidative stress in
neuropsychiatric disorders, the ﬁrst generation of
investigations of therapies that modulate redox biology
have been promising.5 In addition, the ﬁrst studies
targeting mitochondrial dysfunction are underway.
Disruptions of the circadian system are also found in
mental disorders, and novel treatments for re-
synchronising these systems (bright light, melatonin
receptor agonists) offer new approaches to therapy.6
A key element underpinning biological models of mental
illness is the genetic component. High hopes of identifying
a single gene for speciﬁc psychiatric disorders have
evaporated with the advent of molecular genetics. In the
disorders with the greatest heritability, numerous single
nucleotide polymorphisms (SNPs) have been identiﬁed,
each ofwhich alone has only a veryweak effect. More than
100 SNPs associated with schizophrenia have been
identiﬁed by genome-wide association studies. A genetic
relationship with the major histocompatibility complex
locus has been described, and complement component 4
(C4) alleles that affect the expression of C4A and C4B
proteinshaverecentlybeenassociatedwith schizophrenia;7
functionally, theseﬁndingsmayoffer anexplanation for the
loss of cortical grey matter in people with schizophrenia.
Theyalso concurwithmuchearlier biomarkerﬁndings that
implicated abnormalC4 expression in thepathophysiology
of depression.8 This illustrates that bottom-up biomarker
and top-down genetic approaches can complement each
other in clarifying the pathogenesis of psychiatric
disorders. Additionally, in silico approaches have been
used in hypothesis generation for detecting potential
therapeutic agents.9
However, it needs to be stressed that almost all
current therapies arose by exploiting serendipitous
clinical ﬁndings, and it makes sense not to abandon this
avenue of drug discovery.10 It remains crucial that clinical
acuity and research platforms such as epidemiology
continue to be utilised, to facilitate the detection of
unexpected associations between treatment and clinical
disease burden. A clear understanding of biological
models of psychiatric dysfunction and how they interact
and complement each other, using the full array of
neuroscientiﬁc approaches available, remains essential
for developing more effective therapies for disabling
mental disorders. But this needs to be an iterative and
bi-directional process, with back translation of clinical
ﬁndings to reverse engineer neurobiology, historically a
fruitful avenue for uncovering the underlying
pathophysiology of these disorders.
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